Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 129.73B P/E 18.00 EPS this Y -89.20% Ern Qtrly Grth -19.00%
Income -6.54B Forward P/E 8.64 EPS next Y 819.70% 50D Avg Chg -4.00%
Sales 46.51B PEG -14.47 EPS past 5Y 10.73% 200D Avg Chg -12.00%
Dividend 4.00% Price/Book 4.03 EPS next 5Y -4.81% 52W High Chg -24.00%
Recommedations 2.80 Quick Ratio 0.94 Shares Outstanding 2.03B 52W Low Chg 3.00%
Insider Own 0.11% ROA 6.00% Shares Float 2.02B Beta 0.46
Inst Own 77.93% ROE -26.59% Shares Shorted/Prior 21.79M/28.01M Price 61.75
Gross Margin 76.18% Profit Margin -14.06% Avg. Volume 8,754,443 Target Price 52.25
Oper. Margin 21.29% Earnings Date Oct 31 Volume 9,548,659 Change 0.36%
About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company News
06:11 AM The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Arthur J. Gallagher, TC Energy and Bridger Aerospace
06:00 AM With 77% institutional ownership, Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst the big guns
10/11/24 Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
10/11/24 Top Research Reports for Bristol-Myers, Arthur J. Gallagher & TC Energy
10/09/24 BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
10/09/24 Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
10/07/24 Old Drug Repurposed for Schizophrenia Could Reap Alzheimer’s Windfall
10/05/24 Bristol-Myers Squibb Company (BMY): A Buzzing AI Health Stock to Add to Your Portfolio
10/05/24 These 4 Measures Indicate That Bristol-Myers Squibb (NYSE:BMY) Is Using Debt Reasonably Well
10/04/24 Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
10/04/24 Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
10/04/24 BMS receives FDA approval for Opdivo to treat NSCLC
10/03/24 Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
10/03/24 U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
10/03/24 Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
10/03/24 2 Passive Income Stocks to Load Up On in October
10/02/24 STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
10/01/24 PRME Stock Rises 11.8% on Collaboration With Bristol Myers
10/01/24 A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
10/01/24 BMS and Prime ink potential $3.5bn deal to develop T cell therapies
BMY Chatroom

User Image ThrowinDice Posted - 48 minutes ago

$BMY interesting...https://www.gbnews.com/health/cancer-breakthrough-new-miracle-treatment-brain-cure

User Image vanguard100 Posted - 4 hours ago

$BMY

User Image stiselini Posted - 7 hours ago

Took profits on $BMY. Feel like technicals are glitchy at the moment.

User Image 30AMoney Posted - 7 hours ago

$SPY $BMY dec 20 35p's @ $.05 (A Player sold 85 units). i like this trade~

User Image Vnso123 Posted - 9 hours ago

$PRME any additional share purchasing from $GOOG or $BMY is going to launch this into space. Trading at a big discount right now!

User Image FridayGuy Posted - 22 hours ago

$BMY If this stock beats 2 quarters in a row come 10/31/24 we are going to run hard to the upside

User Image PennyFun Posted - 23 hours ago

$BMY 60$ coming ;holding form 40s 💚✅💚✅

User Image Mike_Check1 Posted - 1 day ago

@onefryshy @ThatStockGuy4 aside for the schizophrenic drug i personally will begin Breyanzi treatment next week. I got insurance but saw how much the insurance company will be paying. My yearly treatment will cost $98,000 most of that going to $BMY. That drug only will be making them hundreds of millions next year.

User Image TalkMarkets Posted - 2 days ago

Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12 $JNJ Also $BMY $LLY $ABBV https://talkmarkets.com/content/stocks--equities/johnson--johnson-dividend-stock-analysis-saturday-oct-12?post=465050

User Image ThatStockGuy4 Posted - 3 days ago

Generally #bearish on $BMY. Seems to to have been good value for quite some time but the market doesn't agree & price is what pays.

User Image ClosetIguana Posted - 3 days ago

$BMY

User Image Quantumup Posted - 3 days ago

Piper Sandler raised the PT on $EWTX to $51 was $48 and reiterated at an Overweight rating. Piper Sandler says in its research note: Into 12-month Ph2 CANYON data (December), we think BMD represents a free call option investors aren't recognizing. Specifically, Street expectations are low, but even if sevasemten shows stat sig on CK with directional NSAA trends (base case), this could potentially support a case for accelerated approval filing to drive positive stock movement. Homerun would be stat sig across the board on CK & NSAA, which could strongly enable EWTX to file on these data, thus drive even more share gains (low expectations from investors). Importantly, we think BMD provides upside; even with a CK miss (unlikely in our view), there would be minimal stock impact as investors' valuation primarily rests on HCM (#8). With that, we increased our PT to $51 following positive EDG-7500 HCM data. $cytk $bmy

User Image starbreaker Posted - 3 days ago

$BMY I regret not pulling the trigger on this back in June when it was deeply oversold and it looked like they had washed out all the negatives in Q1 earnings. The Jan2025 45 calls I was looking at are a 6 bagger now. Dropped the ball.

User Image ClosetIguana Posted - 4 days ago

$BMY Don't let them get you off your shares. Everybody and their dog know we're going to have an ER beat at the end of the month.

User Image heweg11 Posted - 4 days ago

$BMY

User Image brief1066 Posted - 4 days ago

$BMY dead to me

User Image m5pmc Posted - 4 days ago

$BMY wtf is with the PA

User Image TheProphetOfProfit Posted - 4 days ago

This has very much been a week of consolidation for $BMY after seeing a breakout of this 12 month inverted head and shoulders on the weekly last week. I still think this will move higher in the coming weeks.

User Image ThrowinDice Posted - 4 days ago

$BMY grinding to $55 by 10/18 with a drop back to $52.50 a the end of the month...$60 before year end if the world doesn't fall apart...

User Image TechnicallySaved Posted - 4 days ago

Hope ya'll didnt let that dip shake you out. Almost pushed the sell button myself but still holding and still predicting $ 55 by 10/18 $BMY https://technicallysaved.com/bullish-on-bmy/

User Image DocPharm Posted - 5 days ago

@thebenchwarmers @EdDwg you can listen to any of it and realize VTP (likely) achieves functional cure of hepatitis B in a great majority of patients with baseline HbSAg <200 IU To get there you need to knockdown that antigen load. How do you knockdown or knockdown expression of a gene? RNAi - Ribonucleic Acid interference / silencing What company has the best TPP thus far in development for a HBV RNAi & already generating data with said RNAi? $ABUS - Imdusiran $BRNS - VTP-300 $BMY could be our suitor. - Nivo seems to be the gem - The roots of the executives, advisory council, and board members of ABUS align -Opdivo loses patent exclusivity in a couple years, AB-101 bridge could reopen that blockbuster potential in other indications

User Image IN0V8 Posted - 5 days ago

$BMY UBS raises target price to $54 from $50

User Image abubnic Posted - 5 days ago

$BMY is up +33% since July. $PFE is up +20% since April. And there are all those dividends in between.

User Image DefenseMania Posted - 5 days ago

$GILD $AZN $PFE $BMY https://finance.yahoo.com/news/arcus-biosciences-present-first-clinical-120000335.html

User Image PFElinepfrenzy1990 Posted - 5 days ago

$BMY - Good.

User Image oldtrader60 Posted - 5 days ago

$BMY They BTFD

User Image onefryshy Posted - 5 days ago

$BMY Great article in the Wall Street journal yesterday about how their schizophrenic drug may be pertinent to Alzheimer's as well.

User Image DocPharm Posted - 5 days ago

@thebenchwarmers @thebenchwarmers leaning towards nivolumab and then talking with $BMY on how to bridge the data from Opdivo to Ab-101. Much of then data can be bridged once they have the SAD/MAD data &amp; that’s for oncology too

User Image Quantumup Posted - 5 days ago

H.C. Wainwright⬆️the PT on $CYTK to $120 was $90 and reiterated a Buy rating. Ahead of next week's CMI focused R&D Day, HCW considers how busy Cytokinetics is and the five major themes to the investment case right now, in its beliefs: $bmy $ewtx

User Image ClosetIguana Posted - 5 days ago

$BMY It's time

Analyst Ratings
BMO Capital Market Perform Sep 27, 24
BMO Capital Market Perform Sep 23, 24
Cantor Fitzgerald Neutral Sep 16, 24
Jefferies Hold Aug 28, 24
Barclays Underweight Aug 22, 24
TD Cowen Hold Aug 12, 24
Barclays Underweight Jul 29, 24
Deutsche Bank Hold Jul 23, 24
Cantor Fitzgerald Neutral Jul 22, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BOERNER CHRISTOPHER S. Chief Executive Offi.. Chief Executive Officer Dec 05 Buy 49.78 2,000 99,560 82,672 12/07/23
BOERNER CHRISTOPHER S. Chief Executive Offi.. Chief Executive Officer Nov 28 Buy 48.86 3,071 150,049 79,384 11/30/23
Samuels Theodore R. II Director Director Nov 20 Buy 49.81 8,500 423,385 35,500 11/21/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Aug 24 Sell 61.25 17,986 1,101,642 27,868 08/28/23
Plenge Robert M EVP, Chief Research.. EVP, Chief Research Officer Aug 03 Sell 61.14 732 44,754 6,584 08/07/23
VESSEY RUPERT EVP & President, Res.. EVP & President, Research May 03 Sell 67.06 50,385 3,378,818 47,751 05/04/23
Caforio Giovanni Board Chair and CEO Board Chair and CEO Feb 06 Sell 74.65 240,000 17,916,000 236,104 02/08/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Feb 06 Sell 74.69 11,183 835,258 23,043 02/08/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Nov 09 Sell 80.45 16,250 1,307,312 34,226 11/14/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 07 Option 54.85 52,604 2,885,329 102,989 11/09/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 07 Sell 78.88 45,910 3,621,381 57,079 11/09/22
Elkins David V EVP, Chief Financial.. EVP, Chief Financial Officer Sep 13 Sell 71.32 133,951 9,553,385 119,786 09/15/22
Elkins David V EVP, Chief Financial.. EVP, Chief Financial Officer Sep 13 Option 48.49 123,277 5,977,702 223,737 09/15/22
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Sep 14 Sell 70.75 25,000 1,768,750 50,476 09/15/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Jun 13 Sell 74.04 30,000 2,221,200 551,104 06/14/22
LEUNG SANDRA EVP, General Counsel EVP, General Counsel Jun 06 Sell 74.89 65,000 4,867,850 308,627 06/07/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Mar 21 Sell 71.52 25,000 1,788,000 581,524 03/23/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Mar 16 Option 53.64 47,305 2,537,440 93,613 03/18/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Mar 16 Sell 69.25 74,559 5,163,211 50,385 03/18/22
Santiago Karen Murphy SVP & Controller SVP & Controller Mar 14 Sell 69.195 6,577 455,096 16,704 03/16/22
BOERNER CHRISTOPHER S. EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 14 Sell 69.197 29,532 2,043,526 41,966 03/16/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Feb 24 Sell 67 30,000 2,010,000 453,455 02/28/22
von Autenried Paul EVP, Chief Informati.. EVP, Chief Information Officer Nov 22 Sell 57.19 51,134 2,924,353 63,536 11/24/21
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Option 48.03 52,213 2,507,790 98,355 11/23/20
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Sell 61.28 57,591 3,529,176 51,343 11/23/20